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Summary
 
Optimal T cell differentiation into effector cells with specialized functions requires the participa-
tion of cytokine receptor signals. In T helper cells, this process is controlled by chromatin changes
and distal and proximal regulatory elements as well as specific transcription factors. Analogous
events during cytotoxic T lymphocyte (CTL) differentiation remain to be identified. This process
is known, however, to be crucially regulated by interleukin (IL)-2 receptor (R) signals. It is ac-
companied by the induction of perforin expression via a mechanism that does not entail proximal
regulatory elements. In this report, transgenically expressed human perforin gene locus DNAs
demonstrate that IL-2R signals target two IL-2–dependent enhancers 
 
z
 
15 and 1 kilobase up-
stream of the promoter. The most distal enhancer may also respond to TCR signals. In transient
transfections, both enhancers required two identically spaced Stat-like elements for their activa-
tion, which was abolished by expression of a dominant negative signal transducer and activator of
transcription (Stat)5 molecule, whereas a constitutively active Stat5 molecule bypassed the re-
quirement for IL-2R signals. These results provide a molecular explanation for the activation of
the perforin gene during CTL differentiation and complement the analysis of animals deficient in
the activation of the IL-2R Stat signaling pathway by establishing perforin as a target gene.
Key words: cytotoxic T lymphocyte • IL-2 receptor • T cell activation • perforin •
transgenic mouse
 
R
 
ecognition of intracellular pathogens by the immune
system leads to the differentiation of peripheral CD8
 
1
 
T cells into effector CTLs with lytic capacity. This process
involves signals from both the TCR and cytokine receptors.
TCR signals assure the specificity of a CTL response. Cy-
tokine signals not only sustain the proliferation of CTLs but
also induce and fine tune the expression of genes required
for the cytotoxic function, such as the expression of perforin.
Perforin is an inducible component of the lytic machin-
ery of CTLs (1–3) and thus part of the adaptive immune sys-
tem. As a constitutive component of NK cells (2), it is also
part of the innate immune system. The release of perforin
onto target cells results in the formation of large transmem-
brane channels (4). The pore formation may be lytic on its
own, or it can provide conduits for other effector molecules,
such as granzymes (5). Despite other cytotoxic mechanisms
(6), perforin expression plays a nonredundant role for the
clearance of certain noncytopathic viral infections (7, 8). It
also participates in the clearance of infections with intracel-
lular bacteria (9) and in the surveillance of emerging tumors
and the rejection of established tumors (10).
Perforin expression is undetectable in naive CD8
 
1
 
 cells,
but it is upregulated in virtually all CTLs of the effector
phenotype (11). Perforin is also expressed by some acti-
vated CD4
 
1
 
 T cells (12, 13). The concise activation require-
ments for perforin induction in CD4
 
1
 
 T cells and their bio-
logical role in vivo remain to be clarified. On the other
hand, IL-2 and IL-15 have been shown to directly induce
perforin gene expression in CD8
 
1
 
 T cells (1–3, 14, 15).
Both cytokines lead to identical signals because their recep-
tors are comprised of identical signaling chains, namely IL-
2R
 
b
 
 and IL-2R
 
g 
 
(16). It is important to emphasize that
naive CD8
 
1
 
 T cells express both chains, in contrast to na-
ive CD4
 
1
 
 T cells, which lack detectable levels of IL-2R
 
b
 
(17). This differential expression of IL-2R
 
b
 
 provides one
molecular explanation as to why naive CD8
 
1
 
 cells, but not
naive CD4
 
1
 
 cells, are able to respond to high doses of IL-2
without prior TCR signals (13). The important role of IL-
2R or IL-15R signals for the generation of effector CTLs
in vivo is consistent with the inability of IL-2R
 
b
 
–deficient
animals to generate virus-specific effector CTLs (18). Hence,
the molecular characterization of the inducible expression 
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of perforin by IL-2R signals may offer insights into the ac-
tivation/differentiation processes of CTLs.
Previous investigations by several laboratories have fo-
cused on transcriptional events mediated by the mouse per-
forin promoter. Using different approaches, three distinct
mechanisms were implied: Cooperation between Sp-1 and
Ets-related transcription factors acting on the proximal pro-
moter (19); an effector CTL–specific posttranslational mod-
ification of a ubiquitous Ets-related transcription factor
binding to an Ets-consensus in the distal promoter (20, 21);
and gene derepression by two distal promoter elements and
two nuclear proteins expressed by noncytolytic cells (22,
23). These mechanisms involving the perforin promoter
may complement each other, providing a reasonable expla-
nation for the T and NK cell–restricted expression of per-
forin in vivo in normal cells, based on the analysis of the
perforin promoter in transgenic mice (24). Unexpectedly,
however, they could not provide insight into how perforin
expression is induced upon T cell activation, because trans-
gene expression by perforin promoter–transgenic mice is
constitutive and not upregulated by IL-2 or other T cell ac-
tivation signals (24). Our study was undertaken to reveal
the molecular basis for how IL-2R signaling regulates the
perforin gene.
 
Materials and Methods
 
Identification and Characterization of SAM-19 Cells.
 
SAM-19 cells
were derived from the autonomously growing mouse CTL/rat
thymoma hybrid PC60 (25) that cannot be activated by IL-2 on
its own to express perforin (26). We noticed a weak IL-2 response
of the perforin gene in a subline designated SA. Further analysis
indicated that the SA line, but not the other lines, contained cells
constitutively expressing the mouse IL-2R
 
b
 
 chain. Constitutive
expression of mouse IL-2R
 
g
 
 was equivalent in all lines. After
cloning these cells at the single-cell level, one clone, SAM-19,
was obtained that expressed IL-2R
 
b
 
 mRNA at levels equivalent
to those in the CTL effector–like CTLL-2 line. Neither resting
nor IL-2–stimulated cells expressed detectable levels of mouse
IL-2R
 
a
 
 protein or mRNA. As described for T cells exclusively ex-
pressing IL-2R
 
b 
 
and IL-2R
 
g
 
 (27), SAM-19 responded to recom-
binant mouse IL-2 at concentrations 
 
.
 
100 U/ml with the induc-
tion of the mouse perforin and granzyme B genes. Half-maximal
levels of perforin mRNA were detected after 
 
z
 
14 h of induction.
Maximum levels were induced after 
 
z
 
48 h. Cell counts of SAM-
19 cultures maintained in the presence of 500 U/ml IL-2 versus its
absence did not significantly differ from each other, suggesting
that IL-2R signaling has little or no effect on the growth and sur-
vival of SAM-19. The cells were maintained in IMDM supple-
mented with 10% FBS, 5 
 
3
 
 10
 
2
 
5
 
 M 
 
b
 
-ME, and 50 
 
m
 
g/ml genta-
mycin.
 
Northern Blot and Nuclear Run-On Analysis.
 
Total RNA was
extracted and analyzed as described (28). Purification and RNase
treatment of nuclei as well as the elongation reactions and their
purifications were performed as described (29) using 
 
z
 
2.5 
 
3
 
 10
 
7
 
nuclei and 240 
 
m
 
Ci of 
 
a
 
-[
 
32
 
P]UTP (800 Ci/mmol) per reaction
(15 min at 30
 
8
 
C). Hybridizations were carried out with 1.6 
 
3
 
10
 
7
 
/ml TCA-precipitable counts for 36 h at 65
 
8
 
C in 10 mM Tris,
pH 7.5, 10 mM EDTA, pH7.5, 0.3 M NaCl, 1% SDS, 250 
 
m
 
g/ml
tRNA, 1
 
3
 
 Denhardt’s solution, and 0.5% nonfat dry milk. Filter
 
washes, including an RNase A digestion, have been described
(29). Target probes were obtained by PCR of genomic DNA
and cloned as follows. The 
 
b
 
2
 
-microglobulin probe (nucleotides
3,942–4,384 of sequence available from EMBL/GenBank/DDBJ
under accession number M18837) and the 5S ribosomal RNA
probe (nucleotides 268–449 of sequence available from EMBL/
GenBank/DDBJ under accession number X51545) were cloned
into pCRII (Invitrogen Corp.). The perforin 5
 
9
 
 probe containing
the short first exon and the beginning of the first intron (nucle-
otides 830–1,156 available from EMBL/GenBank/DDBJ under
accession number M95527) and the perforin 3
 
9
 
 probe containing
part of the third exon (nucleotides 101–464 of sequence available
from EMBL/GenBank/DDBJ under accession number X51446)
were cloned into M13 mp18, and single-stranded phage DNA
containing perforin antisense DNA was produced. 10 
 
m
 
g dena-
tured DNA was slot blotted for each target. All constructs were
confirmed by sequencing.
 
Human Genomic Perforin Clones and Reporter Gene Constructs.
 
The two genomic clones depicted (see Fig. 2) were obtained by
screening a commercially available human placenta pWE15 cosmid
library (Stratagene Inc.) on duplicate filters with a human per-
forin exon III probe and a human perforin promoter probe. They
were further analyzed by restriction mapping and Southern hy-
bridization to these two probes. All analyzed fragments matched
the results of genomic Southern blots. Also, the sequence of a
promoter fragment of both clones was identical to the one we re-
ported previously (30). The initial reporter gene construct was as-
sembled by cloning a KpnI–SfiI fragment (
 
2
 
15,600 to 
 
2
 
277)
into the promoterless pGL3 basic reporter vector (Promega Corp.),
in which the remaining human perforin promoter, exon I, intron I,
and the untranslated sequences of exon II had been fused to the
firefly luciferase gene. Constructs without the first intron used an
EcoRV site at 
 
1
 
59. The progressive deletion constructs (see Fig. 3)
were obtained by exonuclease treatment of a KpnI (
 
2
 
15,600)-
and HindIII (
 
2
 
13,300)-digested plasmid, followed by Klenow
and T4 DNA polymerase treatment, gel purification, and religation.
All constructs were transformed by electroporation into DH10B
cells (Life Technologies). Other deletions, including internal de-
letions, were created by restriction enzyme digestion followed by
T4 DNA polymerase treatment and religation of the vector. The
analysis of the upstream enhancer (see Fig. 4 B) also involved the
cloning of PCR fragments, all of which were verified by se-
quencing both strands of the enhancer. Mutations of the signal
transducer and activator of transcription (Stat)
 
1
 
 elements were intro-
duced using the QuickChange site-directed mutagenesis kit from
Stratagene Inc. After verification of the sequences on both strands of
the enhancers, they were recloned into a fresh vector to eliminate
second-site mutations outside of the sequenced DNA. The domi-
nant negative Stat5a expression vector was generated similarly.
 
Stable and Transient Expression Studies.
 
Vector backbone–free
DNA for stable transfections employed NotI sites flanking the in-
serts of the pWE15 cosmid clones or the NotI and SalI sites of
the pGL3 reporter vectors. For stable transfections, an 
 
z
 
5:1 mo-
lar excess of the perforin transgene over a selection cartridge con-
taining a TK promoter driving the neomycin gene in a total of 40
 
m
 
g DNA was transfected into 400 
 
m
 
l of 2.5 
 
3 
 
10
 
7
 
/ml SAM-19
in DMEM supplemented with 4.5 g/liter glucose and 25 mM
Hepes by electroporation of a 4-mm gap cuvette with an ECM600
system (BTX) set to 230 V, 3,000 
 
m
 
F, and 24 
 
V
 
. The washed
cells were cultured for 15–17 h in 2 ml of complete growth me-
 
1
 
Abbreviations used in this paper:
 
 AP, activator protein; CsA, cyclosporin A;
Stat, signal transducer and activator of transcription. 
1299
 
Zhang et al.
dium, washed again, and selected as 2 
 
3
 
 10
 
4
 
/ml live cells (1.0 ml
per well in a 48-well plate) in the presence of 1.3 mg/ml active
G418 (Life Technologies). 2–3 wk later, G418-resistant clones
were expanded and screened by PCR for the presence of human
perforin promoter sequences. PCR-positive clones were further
analyzed by genomic Southern blot of restriction-digested DNA
side-by-side with digested human genomic DNA to determine
the integrity of the transgenic constructs and to estimate the copy
numbers of the transgene. Transgenic mice, generated as we de-
scribed previously (24), were analyzed accordingly.
Electroporation conditions for transient transfections were
identical but used less DNA (indicated in the figure legends) and
included an internal control plasmid, pRL-CMV (Promega Corp.)
in which a CMV promoter drives the renilla luciferase gene. Af-
ter the electroporated cells were washed, they were split into two
500-
 
m
 
l aliquots (three aliquots for activations using pharmacolog-
ical agents), rested for 1–3 h, and then supplemented with 500 
 
m
 
l
of medium with or without recombinant mouse IL-2 (and/or
pharmacological agents), providing a final concentration of 600
U/ml. After overnight incubation for 15–17 h, the cells were
washed with PBS and lysed and extracted in 50–80 
 
m
 
l passive ly-
sis buffer (Promega Corp.) by two rounds of freeze thawing. Re-
porter gene activities were determined in three 10-
 
m
 
l aliquots of
each extract using the dual luciferase assay system from Promega
Corp. and a ML2250 96-well plate luminometer (Dynex Tech-
nologies). Signals were integrated for 10 s for both luciferase ac-
tivities. The ratios of firefly luciferase activity to renilla luciferase
activity varied by 
 
,
 
5% in the triplicate measurements. Their av-
erage was used to represent the analysis of each independently
transfected sample.
 
Results
 
Perforin Gene Regulation in the SAM-19 Model.
 
An im-
portant limitation in the study of antigen- and/or growth
factor–dependent CTL clones is that they downregulate
their overall RNA and protein synthesis and begin to apop-
tose when deprived of stimuli. In fact, the time periods re-
quired to “downregulate” the perforin gene to study its
“activation” considerably overlap with this generalized cell
shutdown. Therefore, we established a novel CTL tissue
culture model, designated SAM-19, to facilitate the study
of perforin gene induction by IL-2R signaling. SAM-19 is
an autonomously growing, growth factor–independent
clone derived from a mouse CTL–rat thymoma hybrid (see
Materials and Methods). These cells respond to high doses
of mouse IL-2 with the induction of mouse perforin and
granzyme B mRNAs with kinetics similar to those ob-
served in primary cells (3). The induction of the perforin
gene by IL-2 did not depend on newly synthesized proteins
(Fig. 1 A), and the mRNA induction was not regulated at
the posttranscriptional level (data not shown), properties
analogous to those of primary CTLs (3). In addition, per-
forin mRNA induction in SAM-19 was not blocked by
rapamycin (Fig. 1 B), as reported for primary cells (31).
Taken together, SAM-19 appears to comprise a reasonable
in vitro model with which to study perforin gene regula-
tion by IL-2R signals.
Before undertaking more detailed studies, we considered
the possibility that IL-2–unresponsive constitutive expres-
sion by the mouse perforin promoter in transgenic mice
(24) could have been due to a regulation at the level of
transcription elongation. As assayed by nuclear run-on analy-
sis, however, transcription of the 5
 
9
 
 and 3
 
9
 
 ends of the per-
forin gene were induced by IL-2 to similar levels (Fig. 1 C).
These data indicate that IL-2R signals regulate the perforin
gene at the level of transcription initiation via regulatory
domains other than its promoter.
 
Transgenic Perforin Gene Regulation in SAM-19 and in Primary
T Cells.
 
An expression screening strategy was used to
identify putative regulatory domains other than the promoter.
This approach was facilitated by the compact dimension of
the human perforin gene (Fig. 2), the ability to distinguish
Figure 1. Regulation of mouse perforin mRNA induction by IL-2 in
SAM-19. (A) Perforin mRNA induction does not require newly synthe-
sized proteins. SAM-19 cells were activated for the indicated times with
1,000 U/ml IL-2 in the presence or absence of 40 mM cycloheximide
(CHX), which blocked .95% of protein synthesis (data not shown). To-
tal RNA was analyzed by Northern blot analysis. (B) Perforin mRNA in-
duction is not inhibited by rapamycin. Total RNA was extracted from
SAM-19 activated for 24 h with 1,000 U/ml IL-2 in the presence of the
indicated concentrations of rapamycin and analyzed by Northern blot
analysis. G3PDH denotes the glyceraldehyde-3-phosphate dehydrogenase
mRNA. (C) Perforin mRNA induction occurs at the level of transcrip-
tion initiation. Nuclei of SAM-19 cells maintained in medium versus
1,000 U/ml IL-2 for 24 h were analyzed by run-on assays in both the ab-
sence and presence of 1 mg/ml a-amanitin, which was included to docu-
ment that transcripts detected for perforin (59 vs. 39 end of the transcribed
gene; see Materials and Methods) and b2-microglobulin (b2-m) but not
for the 5S ribosomal RNA gene (5S; transcribed by RNA polymerase III)
were elongated by RNA polymerase II. Identical numbers of incorpo-
rated counts were hybridized to each filter. 
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the human and the mouse perforin mRNAs from each
other, and the transfectability of SAM-19. In initial experi-
ments, two suitable human gene locus DNAs from a cosmid
library were stably transfected into SAM-19. The expres-
sion of both the 
 
2
 
16,500 and 
 
2
 
20,700 DNAs was regu-
lated by IL-2 in several independent clones (Fig. 2). This
suggested that these DNAs contained IL-2–responsive cis-
acting sequences in their overlapping regions. Further ef-
forts focused on their 5
 
9 
 
flanks, because we failed to detect
transcriptionally relevant DNA in transient transfections of
the intragenic DNA and the 3
 
9
 
 flank of the 
 
2
 
20,700 gene
locus DNA. Indeed, a restriction fragment comprising most
of the cloned 5
 
9
 
 flank fragment also drove a transgenic lu-
ciferase reporter gene in an IL-2–responsive manner (Fig. 2,
 
2
 
15,600), in contrast to a promoter construct (
 
2
 
277). In-
terestingly, an intermediate construct (
 
2
 
5,300) responded
at intermediate levels, which was shown in further investi-
gations to be due to the presence of two regulatory do-
mains rather than one. Unlike the inducibility of the trans-
genes, their levels of expression in relation to the transgenic
copy numbers varied considerably in all clones, suggesting
that these DNAs do not contain additional constitutive en-
hancers, silencers, or a locus control region.
To extend the results from the stable transfections of
SAM-19 to normal T cells, a 
 
2
 
15,600 to 
 
1
 
59 perforin/
luciferase construct was analyzed in transgenic mice. Two
founders did not express luciferase activity at all, neither in
resting nor activated peripheral lymphocytes. The other two
founders expressed the transgene, with its expression regu-
lated by IL-2R as well as TCR signals, including the cross-
linking of CD3 or PMA plus ionomycin (Table I). The rates
of induction for luciferase protein observed in the transgenic
mice were higher than those in the SAM-19 system. Based
on our experience with a transgenic CD4 reporter gene (24),
this may reflect a global increase in the translation efficiency
upon activation of freshly obtained primary T cells. More
importantly and unlike the previously investigated promoter
transgenes, the 
 
2
 
15,600 to 
 
1
 
59 perforin/luciferase-trans-
genic T cells clearly responded to activation signals.
 
Characterization of Two IL-2–responsive Enhancers.
 
To ad-
dress exactly where the IL-2–responsive cis-acting DNA
was located, progressive deletions of the construct analyzed
in transgenic mice were assayed in transient transfections. A
consistent pattern for their IL-2 responses was noted (Fig.
3 A). The most 5
 
9
 
 deletion (from 
 
2
 
15,600 to 
 
2
 
13,300) re-
sulted in an impaired IL-2 response. This response was abol-
ished once sequences downstream of 
 
2
 
1,450 were deleted.
This finding suggested the presence of two cis-acting DNAs,
consistent with the intermediate levels of response seen
previously in the stable transfections of the reporter con-
struct of intermediate length (Fig. 2). This interpretation
was also consistent with the reporter analysis of internal de-
letions (Fig. 3 A, bottom). The deletion of the sequences
residing between the two putative domains as well as the
spacing between the two domains did not impair the levels
of regulation observed by the entire 5
 
9
 
 flank. Finally, the
far-upstream regulatory domain on its own also conferred
Figure 2. Structure and cis-acting function of trans-
genic human perforin genes in SAM-19 cells. The hu-
man perforin gene locus consisting of three exons (ref-
erence 30) is depicted at top (UT, untranslated
sequence). Below are the genomic DNAs and chimeric
reporter constructs whose expression was analyzed be-
fore and after overnight stimulation with IL-2 in the
indicated number of stably transfected, independent
clones. Expression of the human perforin gene was an-
alyzed by Northern blot, and a representative is shown
for each genomic DNA. Note that the human perforin
probe did not crosshybridize with the endogenous
SAM-19 murine mRNA under our experimental con-
ditions. Values under inducibility represent the mean
and standard deviation after correction of the densito-
metrically quantitated Northern blot data for G3PDH
or respectively after correction of the luciferase activity
for the protein content of the extracts. Three clones
did not express human perforin detectable by Northern
blot analysis (two clones for the –16,500 DNA and one
clone for the 220,700 DNA). They were excluded
from the statistical analysis.
 
Table I.
 
The Human Perforin 5
 
9
 
 Flank (215,600 to 159) 
Promotes Regulated Reporter Expression in Transgenic Mice
Time Medium P P 1 I TCR IL-2
h
0 1 (standard) – – – –
24 1 3 19 21 6
48 1 1 14 16 18
Splenic T cells of transgenic offspring (eight copies) were purified by
magnetic microparticles conjugated to Thy1.2 mAb (MiniMACS™
system; Miltenyi Biotec). Luciferase was extracted from 106 purified
cells (.95% CD31 and z40% CD81) immediately and after culture for
24 and 48 h. Activations involved 10 ng/ml PMA (P) plus 1 mM ion-
omycin (P 1 I), cross-linking of CD3 (TCR; plate-bound 2C11
mAb), and 1,000 U/ml IL-2 (IL-2). Aliquots were measured in dupli-
cate, and their average was used to calculate the fold inductions in ref-
erence to the activity obtained from cells prior to their in vitro culture
(set as 1).1301 Zhang et al.
an IL-2 response to the unresponsive perforin promoter (Fig.
3 A, last construct). Both regulatory domains required the
context of a promoter (data not shown), indicating that
neither comprised a second promoter. The responses by
each individual domain appeared to be additive, suggesting
that their functions were independent of each other within
the experimental context.
The far-upstream regulatory DNA identified in the tran-
sient transfections comprised the very end of the 215,600
construct, whereas both of the original gene locus DNAs
extended farther upstream and appeared to respond some-
what more to IL-2 (Fig. 2). Therefore, the remainder of
the cloned DNA was analyzed to delineate the 59 and 39
borders of the far-upstream regulatory DNA (Fig. 3 B).
This led to an NsiI–BalI fragment that retained the max-
imal response of the far-upstream regulatory DNA (Fig.
3 B, bottom). This fragment also functioned in the context
of the heterologous SV40 promoter (Fig. 4 A). IL-2 in-
creased the transcriptional activity of the constructs over
the promoter levels irrespective of the orientation of the
regulatory DNA. These attributes were consistent with an
IL-2–inducible enhancer, whose required core was con-
tained within z150 bp (Fig. 4 A, bottom). The analogous
experiments for the upstream regulatory domain recapitu-
lated these findings and localized this enhancer within
z130 bp (Fig. 4 B).
Second Messenger Pathways Involved in the Activation of the
Perforin Enhancers.  Consistent with the rapamycin insen-
sitivity of perforin mRNA induction by IL-2 (Fig. 1 B),
the activation of the enhancers was not blocked by rapamy-
cin (Fig. 5 A) at concentrations that abolished granzyme B
induction (Fig. 1 B).
Because perforin mRNA can also be induced in primary
CTLs by TCR signals (2), SAM-19 was activated with
pharmacological agents known to mimic TCR signals, namely
phorbol ester and ionomycin. These agents induce perforin
mRNA in SAM-19 in the absence of detectable IL-2 (data
not shown). Regarding the involvement of the identified
enhancers in this process, the far-upstream enhancer, but
not the upstream enhancer, was significantly activated in
SAM-19 (Fig. 5 B, top). This activation was sensitive to
cyclosporin A (CsA),1 indicating that calcineurin partici-
pated in the activation of the enhancer. These findings sug-
gest that the far-upstream enhancer may also respond to
TCR signals.
The T and NK cell–restricted expression of perforin
raised the additional question of whether activation of the
enhancers by pharmacological agents might be lineage spe-
cific. There was no substantial activation of either enhancer
in the J588L B cell or the L929 fibroblast model (Fig. 5 B,
center and bottom). These data suggest that the enhancers
can be activated primarily in T cells.
Lastly, participation of the Jak/Stat signaling pathway
from the IL-2R was investigated, because both enhancers
contained Stat-like elements. Coexpression of a dominant
negative signal transducer and activator of transcription
(Stat)5 molecule (32) blocked the activation of both en-
hancers by IL-2R signals in a dose-dependent manner, in
contrast to the cotransfections with the parental wild-type
Stat5 expression vector (Fig. 5 C). These data imply that
Figure 3. Identification of two IL-2–respon-
sive regulatory domains in the human perforin
59 flank. (A) Transient transfection analysis of 59
progressive and internal deletions. The genomic
DNAs depicted at left were used to control fire-
fly luciferase expression in SAM-19 that were
split 1–3 h after electroporation and cultured
overnight for 15–17 h with and without IL-2.
The data are given as the ratio of reporter activ-
ity of activated versus unactivated cells and rep-
resent the averages and standard deviations of
the indicated numbers of independent transfec-
tions. 20 mg of DNA was used, comprising a
12:1 molar excess of the experimental plasmid
over an internal control vector. Its CMV pro-
moter–driven renilla luciferase expression, which
did not respond significantly to IL-2 in SAM-
19, served to correct for sample differences. In
the absence of IL-2, the normalized expression
of all perforin promoter–bearing constructs was
10–40 times the levels obtained from the pro-
moterless construct, with no reproducible cor-
relation to any particular construct. (B) Further
characterization of the far-upstream regulatory
DNA. Transient transfection analysis of the de-
picted DNAs in the context of the perforin
promoter (2277 to 159) were performed as
described for A, with the exception of elec-
troporating an 18:1 molar ratio of the experi-
mental plasmids to the internal control vector.1302 Transcriptional Control of Perforin Expression
the activation of Stat5 plays an important direct or indirect
role in the activation of the perforin enhancers by IL-2R
signals.
Both Enhancers Contain Functionally Important Tandem Stat-
like Elements and Can Be Transactivated by Stat5.  Visual and
computer-aided inspection (33) of the sequenced enhancer
cores revealed several similarities to known binding sites or
their cores (Fig. 6 A). Potential binding sites present in
both enhancers at similar positions included two Ets cores,
an activator protein (AP)-1 site and, most strikingly, two
identically spaced Stat-like elements. One closely resem-
bled the consensus dyad symmetry (Fig. 6 A, STAT). The
other element was less well conserved (Fig. 6, 39 STAT-n).
A third less well conserved Stat-like element occurred only
in the far-upstream enhancer (Fig. 6, 59 STAT-n) and
overlapped with the highly conserved element (STAT).
To determine whether these elements were indeed of func-
tional relevance, mutant enhancers were analyzed. Minimal
mutations were designed to selectively interfere with the
potential Stat elements (Fig. 6 A, asterisks). Regarding both
enhancers, a mutation of their 39 STAT-n sites reduced
their transcriptional activation by IL-2 nearly to the levels
of unactivated cells (compare data in Fig. 6 B for constructs
cotransfected with an empty expression vector). A mutation
of their STAT sites or both sites together (double mutant)
completely abolished their enhancer function. In contrast,
mutation of the 59 STAT-n site present only in the far-
upstream enhancer did not impair enhancer activation by IL-2
(Fig. 6 B). These results demonstrate a cooperative require-
ment for both the STAT and the 39 STAT-n site in each
enhancer. Combined with the observed inhibition of en-
hancer activation by a dominant negative Stat5 molecule,
these results suggest that Stat molecules may directly target
these elements.
To address whether Stat molecules could transactivate
the enhancers via the putative elements, a constitutively ac-
tive Stat5 molecule was coexpressed with the perforin en-
hancer reporter constructs. We focused on Stat5 rather than
Stat3 because we could not detect the activation of Stat3 in
SAM-19 upon IL-2R signaling under conditions where ac-
tivated Stat5 molecules were readily detectable (data not
shown). To that end, a chimeric Stat5-VP16-Jak2 mole-
cule that is autoactivated and leads to Stat5-specific DNA
binding and strong transactivation was used (34). Cotrans-
fection with the respective expression vector, but not the
empty expression vector, strongly hyperactivated the wild-
type enhancer, but not the SV40 promoter, in the absence
of IL-2 (Fig. 6 B). Regarding the upstream enhancer, the
transactivation was absolutely dependent on the intact
STAT site and to a lesser extent on the 39 STAT-n site
(Fig. 6 B, left). Additional IL-2R signaling provided some-
what higher levels, suggesting that additional transcription
factors were induced. The analogous transactivation studies
of the far-upstream enhancer (Fig. 6 B, right) were compli-
cated by its additional 59 STAT-n site. As described above,
this site was physiologically irrelevant because its mutation
did not at all impair the IL-2 response. It may have served,
however, as an alternative binding site for Stat5-VP16-Jak2
Figure 4. IL-2–dependent, enhancer-like activi-
ties of the far-upstream (A) and upstream (B) regu-
latory DNA. Fragments of the human perforin
gene locus identified in Fig. 3 were cloned up-
stream of an SV40 promoter. The data summarize
four independent transient transfections of SAM-19
using 20 mg of DNA comprising an 18:1 molar ex-
cess of the experimental plasmid over the internal
control vector as described in Fig. 3. The expres-
sion of the experimental reporter in the absence or
presence of IL-2R signals is given after it was nor-
malized to that derived from the control reporter to
account for variations in the transfection efficiency
and sample differences. These data were used to
calculate the induction.1303 Zhang et al.
when the partially overlapping STAT site had been mu-
tated, because all three sites had to be mutated to com-
pletely abolish the transactivation (triple mutant). Regard-
less, the data presented for both enhancers strongly suggest
that their activation by IL-2R signals is dependent on the
binding of activated Stat molecules to a tandem element,
which may be comprised of a higher affinity site (STAT)
and a lower affinity site (39 STAT-n).
Discussion
Scrutiny of the regulation of the perforin gene is biolog-
ically important and offers a valuable model to shed molec-
ular light on the activation/differentiation of CTLs. This
line of investigation comprises a largely unexplored area in
comparison to analogous investigations of cytokine genes,
which have become widely used as a paradigm toward an
understanding of Th activation/differentiation. In our study
toward deciphering the control of perforin expression by
IL-2, .45 kb of the human perforin gene locus was sur-
veyed in a transgenic tissue culture system (Fig. 2) that
mimics important aspects of perforin gene induction in pri-
mary CTLs (Fig. 1). This analysis led to two IL-2–respon-
sive enhancers in the perforin gene locus (Figs. 3 and 4),
which also promoted inducibility in T cells derived from
transgenic mice, at least in the context of their intervening
genomic sequences (Table I). The activation of both en-
hancers by IL-2 required not only the activation of the Stat
pathway (Fig. 5 C) but also the participation of tandem
Stat-like elements that could be transactivated by Stat5
molecules in our CTL differentiation model (Fig. 6). These
findings suggest that the activation of Stats by IL-2R sig-
nals, in particular the activation of Stat5 molecules, plays an
important role for the generation of CTLs.
Regulation of Perforin Gene Expression and Cytotoxicity by
Stat5. The regulation of the perforin gene by IL-2R sig-
nals via Stat proteins is consistent with several observations
besides the well documented activation of Stat5 and Stat3
by IL-2R signals (35). Stat proteins are latent transcription
factors (36) and, accordingly, the onset of perforin mRNA
induction by IL-2 does not require newly synthesized pro-
teins in our model cell line (Fig. 1 A) nor in primary cells
(3). Similarly, the activation of Stat5 (37), the induction of
perforin mRNA (Fig. 1 B), and the activation of its enhancers
(Fig. 5 A), as well as perforin mRNA induction by IL-2 in
primary cells (31), are all resistant to rapamycin. Con-
versely, TGF-b, which has been suggested to block the ac-
tivation of the Jak/Stat pathway in T cells, including the
activation of Stat5 (38, 39), also prevents the induction of
perforin by IL-2 (40).
Importantly, the analysis of Stat5 knockout animals, as
well as the phenotypes of animals lacking the Stat docking
sites of IL-2Rb, have recently indicated that this IL-2R
signaling pathway may target the perforin gene in vivo and
may be essential for the generation of cytotoxicity. Stat5
exists in humans and mice as two closely related genes with
overlapping expression patterns and, therefore, has an often
redundant role in vivo for both nonlymphoid and lym-
phoid tissues (41, 42). Nevertheless, immunologically rele-
vant phenotypes, albeit perhaps rather discrete, have been
Figure 5. Second messenger pathway require-
ments for activation of the perforin enhancers. (A)
Enhancer activation by IL-2R signals is not blocked
by rapamycin. SAM-19 cells were activated in both
the presence and absence of 0.5 ng/ml rapamycin,
which was shown to abrogate granzyme B but not
perforin mRNA induction (Fig. 1 B). The data
summarize four independent transient transfections
of 20 mg of DNA comprising an 18:1 molar excess
of the minimal enhancer SV40 reporter vectors
(Fig. 3) over the internal control vector. (B) Selec-
tive activation of the far-upstream enhancer by
PMA and ionomycin in SAM-19 CTLs but not in
J558L B cells nor L929 fibroblasts. The indicated
cells were activated with 10 ng/ml PMA plus
1  mM ionomycin (P 1 I) in the absence or pres-
ence of 200 ng/ml CsA. The data summarize three
independent transient transfections (four for SAM-
19) of 8 mg of DNA comprising a 10:1 molar ex-
cess of the minimal enhancer SV40 plasmids over
the internal control vector, as described for Fig. 4.
The data are expressed in relation to the activity of
the promoterless reporter vector, whose normalized
expression in media alone was set as one for each
individual cell line. The data for the activated cells
were corrected for their protein content rather than
expression of the cotransfected marker, because the
CMV promoter responded to PMA and ionomycin. (C) Activation of the perforin enhancers by IL-2 is blocked by coexpression of a dominant negative Stat5
molecule. The data summarize three independent transient transfections of SAM-19 using 15 mg of DNA comprising the tabulated molar ratios of the indi-
cated expression vectors to the minimal enhancer SV40 plasmids (Fig. 3). The two CMV promoter–driven expression constructs are identical, except that
amino acid 750 of murine Stat5a had been mutated into a stop codon to generate a dominant negative molecule as described (32). Transfected cells were split
and cultured in the absence or presence of IL-2. Reporter expression was quantitated and corrected for the protein content of the samples.1304 Transcriptional Control of Perforin Expression
reported for certain single-deficient animals. Stat5a-defi-
cient animals fail to upregulate IL-2Ra in response to IL-2R
signals (43). Stat5b-deficient splenocytes, on the other hand,
poorly generate CTLs in response to IL-2 or IL-15. This
defect, which is accompanied by profoundly reduced but
still detectable levels of perforin mRNA, led to the pro-
posal that perforin is a Stat5-regulated gene (44). This no-
tion is supported by our results. Similarly, splenocytes of
mice expressing an IL-2Rb lacking the Stat docking sites
fail to generate CTLs in response to IL-2 (45).
Redundancy of Stats Activated by IL-2R Signaling. The
redundancy of Stat5a and Stat5b may relate to the incom-
plete block of perforin gene induction by IL-2 or IL-15 in
Stat5b-deficient splenocytes inasmuch as Stat5a-deficient
cells also expressed slightly reduced levels of perforin (44).
The inability of double-deficient T cells to enter the cell
cycle (42) does not allow us to readily address this issue ex-
perimentally due to the relatively long stimulations re-
quired for significant inductions. It is also possible that
Stat5 molecules are facilitators rather than the essential
players for perforin gene activation or that they are redun-
dantly used with Stat3 molecules. Whereas the latter path-
way was not functional in our SAM-19 model (see Re-
sults), another report published while this manuscript was
in preparation indicates that the upstream enhancer of the
perforin gene could also be activated by Stat3 molecules
(46). The authors identified a constitutively enhancing frag-
ment similar to the upstream enhancer of our analysis by
transient transfections of z1,400 bp of the 59 flank into YT
cells, a constitutively perforin-expressing NK cell–like lym-
phoma. The function of this DNA in YT cells was depen-
dent on what is referred to in Fig. 6 as the STAT element,
whereas the 39 STAT-n site was not investigated. Regard-
less, the STAT element was shown to bind constitutively
activated Stat3 molecules present in the YT lymphoma and
Stat5 molecules when extracts of primary NK cells exposed
to IL-2 were applied, suggesting that Stat5 and Stat3 mole-
cules may regulate the upstream enhancer of the perforin
gene. It is conceivable that genes are regulated redundantly
or activation stage specifically by Stat5a, Stat5b, and Stat3
Figure 6. Both perforin enhancers contain tandem Stat-like elements that are required for their IL-2 response and transactivation by Stat5. (A) Se-
quence and putative regulatory elements of the perforin enhancers. Names next to the boxed residues indicate either a potential transcription factor or the
name of the core binding sequence. Boxes extending through the middle indicate potential binding sites that are present in both enhancers. Asterisks in-
dicate the mutations functionally analyzed in B and C. TTTC of the element indicated as 59 STAT-n was changed to CGCT; all other mutations in-
volved A«C and G«T substitutions. The sequence data are available from EMBL/GenBank/DDBJ under accession numbers AF152113 (far-upstream
enhancer) and M31951 (upstream enhancer; nucleotides 311–427 of the deposited sequence). (B) Activation of the upstream enhancer (left) and the far-
upstream enhancer (right) by IL-2 and a constitutively active, chimeric Stat5 molecule. The data summarize four independent transfections of SAM-19
using 22 mg of DNA comprising a 1:2:0.25 molar ratio of the SV40 promoter vector with or without (none) the minimal enhancers shown in A, the in-
dicated expression vector, and the internal control vector. STAT5-VP16-JAK2 is a CMV promoter–driven, constitutively active Stat5 molecule. It de-
notes a fusion of amino acids 1–750 of sheep Stat5 (i.e., Stat5 lacking its endogenous transactivation domain) to the VP16 transactivation domain and the
kinase domain of Jak2 (34). The assayed mutations of each enhancer are indicated in A.1305 Zhang et al.
molecules in T cells, because an impaired upregulation of
IL-2Ra in response to IL-2R signals has been described
not only for Stat5-deficient animals (42, 43) but also for
Stat3-deficient T cells (47).
Role of Stat5 for Lymphoid Lineages Constitutively Express-
ing Perforin. Notably, Stat5 proteins may also play an es-
sential role in the development and/or maintenance of lin-
eages that constitutively express perforin, i.e., NK cells (2)
and g/d T cells (48–50). NK cells are absent in animals de-
ficient in both Stat5 proteins (42), as well as in animals defi-
cient in the ability to activate Stats in response to IL-2R or
IL-15R signals (45). The latter animals also lack g/d intraepi-
thelial lymphocytes, a lineage that so far has not been investi-
gated in the Stat5 double-deficient animals. The biological
relevance of Stat5 molecules and the identified enhancers for
the constitutive expression of perforin by these lineages re-
mains to be analyzed. A constitutively active Stat signaling
pathway in NK cells in vivo, and thereby also an activation
of the perforin gene by the identified enhancers, could be
envisioned based on the expression of IL-15 in virtually all
tissues and the absolute requirement of IL-15R signals for
NK development and/or maintenance (51, 52).
Similar Organization of the Perforin and IL-2Ra Enhancers.
The perforin enhancers and the enhancer of the human and
mouse IL-2Ra genes (53–57) are presently the only sus-
pected Stat5 and Stat3 targets in vivo among genes specifi-
cally expressed by lymphocytes. Interestingly, they are also
similarly organized. Just like the perforin enhancers, the IL-
2Ra enhancer requires a tandem Stat element that serves as
a composite binding site for a tetrameric Stat5 complex bind-
ing individual sites of weaker affinity (55, 57). We are pres-
ently addressing whether the perforin sites, each of which
can bind Stat5 in vitro (Schindler, U., and M.G. Lichten-
held, unpublished observation), also serve as targets for a
tetrameric Stat5 complex, because the spacing of the Stat-
like elements in the perforin enhancers exceeds the spacing
of those in the IL-2Ra enhancers (17 vs. 11 bp). The loss of
enhancer function by an individual mutation of either site
(Fig. 6 B) is consistent with a tetrameric assembly, but these
experiments do not address the mechanism for the ob-
served cooperation. The other element with a major func-
tion in the mouse and human IL-2Ra enhancers entails an
Elf-1–binding Ets core located 14 bp 39 of their tandem
Stat elements (54, 56). This organization is exactly like that
of the far-upstream enhancer of the perforin gene (Fig. 6 A).
An analogous element in the upstream enhancer is located
10 bp 39 of the tandem Stat-like elements. The STAT sites
of both perforin enhancers as well as the 39 STAT-n site of
the upstream enhancer incorporate an Ets binding motif se-
quence core similar to that of the human IL-2Ra enhancer.
This element has been suggested to repress the enhancer in
unactivated cells via an unidentified Ets family protein (54).
Unlike the IL-2Ra enhancer and the upstream enhancer
of the perforin gene, the far-upstream enhancer may respond
not only to IL-2R but also to TCR signals that have been
implied as a second pathway for perforin gene induction (1–3),
because this enhancer also responded to PMA and ionomycin
in a CsA-sensitive manner in SAM-19 (Fig. 5 B). This obser-
vation could suggest a possible role for a nuclear factor of ac-
tivated T cells (NFAT)-like element in the far-upstream en-
hancer whose sequence resembles the “IL140” element of the
IL-3 enhancer, which is known to strongly activate transcrip-
tion independently of AP-1 proteins (58). The physiological
activation of the perforin enhancers is likely to involve tran-
scription factors in addition to Stat5. The combined control
of the perforin enhancers remains to be experimentally estab-
lished and compared with that of the IL-2Ra enhancer.
Based on the inspection of the perforin sequences (Fig. 6 A),
other participating transcription factors could be IL-2 in-
ducible, namely AP-1, cAMP-responsive element binding
proteins, and nuclear factor kb (59–61), or differentially
expressed during lymphoid development, namely Ikaros
proteins (62) and proteins recognizing the E-box (63).
In summary, this study investigates the differentiation
processes of CTLs by working backwards from the perforin
gene. It indicates that the induction of the perforin gene by
IL-2R signals involves at least two enhancers whose activa-
tion is dependent on Stat elements that can be targeted by
Stat5 molecules. These results are consistent with and com-
plement the ongoing findings of the reverse genetics analy-
sis of the IL-2R Jak/Stat signaling pathway.
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